ReviewJournal of psychopharmacology (Oxford, England)2015
Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.
Review in Journal of psychopharmacology (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03288779 (Theta Burst Stimulation for Schizophrenia), which is not on this map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Theta Burst Stimulation for Schizophrenia
Who cites it
61 citing papers in PubMed, 111 citations in OpenAlex.
- Development and testing of a web-based battery to remotely assess cognitive health in individuals with schizophrenia.Schizophrenia research · 2019Trial
- Disorganized Inhibitory Dynamics in Hippocampal area CA1 of 22q11.2 Deletion Mutant Mice.bioRxiv : the preprint server for biology · 2026Article
- IGFBP2-Ceramide Pathway Mediates Divergent Myelin Breakdown in the PNS and CNS Following Injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- The feasibility of culturally adapted computerised cognitive remediation for first-episode psychosis.BJPsych open · 2025Article
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Ketogenic therapy for schizophrenia: evidence, mechanisms, and clinical perspectives.Frontiers in pharmacology · 2025Review
- Ten years ofSchizophrenia research. Cognition · 2024Article
- Reduction of intracortical inhibition (ICI) correlates with cognitive performance and psychopathology symptoms in schizophrenia.Schizophrenia (Heidelberg, Germany) · 2024Article
- Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis.F1000Research · 2024Article
- Review of Major Social Determinants of Health in Schizophrenia-Spectrum Psychotic Disorders: III. Biology.Schizophrenia bulletin · 2023Article
- The Role of Oxytocin in Early-Life-Stress-Related Neuropsychiatric Disorders.International journal of molecular sciences · 2023Review
- Increased Functional Connectivity Involving the Parahippocampal Gyrus in Patients with Schizophrenia during Theory of Mind Processing: A Psychophysiological Interaction Study.Brain sciences · 2023Article
- Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.Wellcome open research · 2023Article
- Schizophrenia: a disorder of broken brain bioenergetics.Molecular psychiatry · 2022Review
- Article
- Clinical and Preclinical Assessments of Anhedonia in Psychiatric Disorders.Current topics in behavioral neurosciences · 2022Article
- Sex-specific effects of polygenic risk for schizophrenia on lifespan cognitive functioning in healthy individuals.Translational psychiatry · 2021Article
- Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment.International journal of molecular sciences · 2021Review
- The Importance of Common Currency Tasks in Translational Psychiatry.Current behavioral neuroscience reports · 2021Review
- Acid Sphingomyelinase Inhibition Mitigates Histopathological and Behavioral Changes in a Murine Model of Traumatic Brain Injury.Journal of neurotrauma · 2020Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Schizophrenia is a life-long debilitating mental disorder affecting tens of millions of people worldwide. The serendipitous discovery of antipsychotics focused pharmaceutical research on developing a better antipsychotic. Our understanding of the disorder has advanced however, with the knowledge that cognitive enhancers are required for patients in order to improve their everyday lives. While antipsychotics treat psychosis, they do not enhance cognition and hence are not antischizophrenics. Developing pro-cognitive therapeutics has been extremely difficult, however, especially when no approved treatment exists. In lieu of stumbling on an efficacious treatment, developing targeted compounds can be facilitated by understanding the neural mechanisms underlying altered cognitive functioning in patients. Equally importantly, these cognitive domains will need to be measured similarly in animals and humans so that novel targets can be tested prior to conducting expensive clinical trials. To date, the limited similarity of testing across species has resulted in a translational bottleneck. In this review, we emphasize that schizophrenia is a disorder characterized by abnormal cognitive behavior. Quantifying these abnormalities using tasks having cross-species validity would enable the quantification of comparable processes in rodents. This approach would increase the likelihood that the neural substrates underlying relevant behaviors will be conserved across species. Hence, we detail cross-species tasks which can be used to test the effects of manipulations relevant to schizophrenia and putative therapeutics. Such tasks offer the hope of providing a bridge between non-clinical and clinical testing that will eventually lead to treatments developed specifically for patients with deficient cognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.